Rheumatol Ther. 2022 Oct 15:1–18 doi: 10.1007/s40744-022-00499-w
Results from the long-term extension of SELECT-PsA 1 show efficacy responses similar or greater with upadacitinib, 15 or 30mg, versus adalimumab through 104 weeks.
In addition, inhibition of radiographic progression was maintained at week 104 and was comparable to that observed previously at week 56. Similar efficacy, including improvements in peripheral arthritis, was observed with upadacitinib 15 mg and 30 mg. No new safety risks were highlighted. These data further support the safety and efficacy of upadacitinib for the treatment of patients with PsA.